Breast Mesh Lawsuits and Internal Bra Complications

Breast mesh lawsuits allege that some manufacturers promoted or allowed their mesh products to become widely used in breast reconstruction, augmentation, and revision procedures despite the fact that FDA has not cleared or approved any surgical mesh product for use in breast surgery. The FDA has specifically stated that the safety and effectiveness of surgical mesh in breast surgery, including augmentation and reconstruction, has not been determined.

These internal bra lawsuits allege that manufacturers of products such as AlloDerm, GalaFLEX, Phasix, AlloMax, FlexHD, Strattice, and DuroSorb marketed their devices for breast reconstruction, augmentation, and revision surgeries even though those breast-specific applications had not been adequately studied or cleared by the FDA. Patients were not warned. Surgeons were not given enough information. So when complications developed, including infection, mesh failure, chronic pain, implant loss, breast deformity, and the need for additional surgery, many women had no reason to connect their injuries to the mesh product placed inside them.

This page explains the internal bra mesh lawsuit. Our lawyers talk about what the legal claims are, who may be eligible, what complications may qualify, how to identify your mesh product, what evidence matters, and what these cases may be worth.

By Ronald V. Miller Jr., Miller & Zois. Updated October 13, 2026.

Who Qualifies to File an Internal Bra Mesh Lawsuit

Different lawyers have different opinions on what constitutes a viable claim in this litigation. Our criteria is pretty aggressive. We are talking to women who had surgical mesh placed during breast surgery and later suffered complications that required a revision (or other serious complication) who are looking to file a breast mesh lawsuit. We do not expect you to call and have every detail about your case before speaking with a lawyer. We are looking for a breast mesh implant and a revision surgery to resolve complications from that implant.

Do you need to have the mesh removed to bring a claim? No. Mesh removal is not mandatory, at least not with our law firm. But the strongest cases usually involve revision surgery or some other powerful evidence — implant loss, removal, significant infection, persistent pain, etc.

So while our law firm is generally focused on cases involving a revision procedure or another serious complication, we suggest you do not screen yourself out too quickly. Tell us what happened to you and see what we can figure out for you.

What Is Breast Mesh and How Is It Used in the Internal Bra Technique?

Think of breast mesh as a hammock placed inside the breast. Depending on the procedure, a surgeon positions the material to help support an implant or surrounding tissue and hold it where the surgeon wants it to stay. That is where the term “internal bra” comes from. An ordinary bra provides support from outside your body. The mesh is meant to provide some of that support from the inside.

The appeal is easy to understand. A woman going through reconstruction after a mastectomy wants a result she can feel comfortable with after everything she has already endured. Someone having a lift or augmentation wants the result to last. The whole idea behind this product is to give the surgeon another way to support that result. But “internal bra” is a reassuring name for something that is actually implanted in your body. You cannot take it off at the end of the day. So pPatients deserve to understand what material is being placed inside them, why it is being used, and what problems it could cause. tion.

Women generally undergo an internal bra procedure for three reasons. First, breast reconstruction surgery following a mastectomy, most often after a cancer diagnosis. Second, breast augmentation, where mesh is used to support implants and maintain shape over time. Third, revision or breast lift surgery, where mesh is used to correct or improve prior procedures.

There are two broad categories of breast mesh:

• Biologic mesh, or ADM: Derived from processed human or animal tissue, acellular dermal matrix acts as a biological scaffold that the patient’s own tissue gradually incorporates. Common brands include AlloDerm, FlexHD, AlloMax, and Strattice.
• Synthetic mesh: Made from man-made polymers, synthetic mesh may be resorbable, meaning it dissolves over time, or permanent, meaning it stays in the body indefinitely. Products that appear in this litigation include GalaFLEX, Phasix, and DuroSorb.

Women like the idea of mesh in breast surgery because the internal bra technique is supposed to reduce mechanical stress on surrounding tissue, support implants, and even extend the longevity of surgical results. Patients and surgeons reasonably assume that a product promoted for breast reconstruction, augmentation, or revision surgery has been studied for that use. We allege that assumption was dead wrong.

So when serious complications occur, the lack of breast-specific FDA review, breast-specific studies, and breast-specific warnings take center stage as we look at whether a lawsuit if viable.

The Internal Bra Lawsuit: What the Legal Claim Actually Says

Breast mesh lawsuits rest on a straightforward legal theory. Manufacturers promoted mesh or ADM products for breast-specific uses and failed to adequately warn patients or physicians about the risks of using those products in the breast.

Understanding how synthetic mesh reached breast surgery starts with the FDA’s 510(k) clearance pathway. Under that process, a device can be cleared for market if FDA finds it substantially equivalent to a predicate device. That is not the same thing as FDA approval of the device for every later clinical use. It is hard to overstate how many medical device lawsuits are from products approved though the 510(k) backdoor.

The BD mesh products identified in the FDA’s November 2023 letter were cleared for repair and reinforcement of soft tissue where weakness exists. Human ADM products can be regulated under a different tissue framework. For example, the AlloDerm SELECT instructions describe regulation as human tissue under 21 CFR Part 1271. Our lawyers need to make sure we have the exact product and the labeling in effect when it was used.

What we allege is that these products became widely used in internal breast procedures and that manufacturers failed to adequately warn patients and physicians about the limits of the FDA clearance and the risks of using mesh in breast tissue. Yes, doctor can use a device off label.  But were they given the information they needed about the product to give patients adequate warnings. They also needed to know that the mesh being implanted in their bodies was not FDA-cleared or approved for breast reconstruction, augmentation, or revision surgery.

Product liability law, specifically failure-to-warn and defective design claims, forms the backbone of most internal bra cases.

Off-Label Use Versus Off-Label Promotion

Doctors often have the discretion to use a medical device off-label when they believe it is appropriate for a particular patient. Everyone agrees it is okay for doctors to do this under reasonable circumstances. But more than ever, if you are going to prescribe something off-label, you really want to know all the downside risks.

Plaintiffs also allege that manufacturers did more than sell a device cleared for general soft tissue reinforcement. They allegedly encouraged breast surgeons to use these products in breast reconstruction, augmentation, revision, and lift procedures without adequate breast-specific testing, without FDA clearance or approval for that use, and without warnings that matched the actual risk profile. That is different from a doctor using a product off-label.

That is why we are suing manufacturers, not treating physicians. Surgeons are not doing studies on these products.  They have to be able to rely on what they are told.

FDA Warnings on Breast Mesh: A Timeline

The FDA’s breast mesh communications give lawyers specific dates and product warnings to compare with the patient’s surgery and the information given to her surgeon.

The FDA’s November 2023 communication concerns specific BD devices cleared through the 510(k) pathway for general soft tissue repair or reinforcement. Human tissue products require a separate review of their regulatory status, labeling, and intended use.

What This Timeline Means for the Breast Mesh Litigation

The progression of FDA attention tells a story plaintiffs’ attorneys have built cases around for years. The FDA eventually raised concerns, and the label language changed. But the women who underwent surgery in 2018, 2019, 2020, or earlier often did so without clear information that the mesh was not cleared or approved for breast surgery. This is a classic failure to warn mass torts lawsuit.

The 2023 label updates are great for women moving forward. But they are of little comfort to women who already had surgery without the benefit of that information. The central questions in this litigation are what manufacturers knew, when they knew it, what they told surgeons, and why breast-specific warnings did not appear earlier.

Breast Mesh Brands Under Legal Investigation

The following surgical mesh and ADM products are under active legal scrutiny in connection with breast mesh injuries. Manufacturers, including Allergan/LifeCell, Becton Dickinson, C.R. Bard, Integra LifeSciences, and MTF Biologics, are named in investigations. If your surgery involved any of these products, you should talk to a lawyer about your claim.

These are just the brands our lawyers are tracking now. If your mesh brand does not appear on this list, you may still have a viable internal bra lawsuit. An attorney can review your records and advise you on whether your specific product and injuries qualify.

GalaFLEX Mesh Lawsuits and Internal Bra Complications

GalaFLEX is a synthetic mesh scaffold. The FDA’s November 9, 2023 letter identified GalaFLEX, GalaFLEX Lite, GalaFLEX 3D, and GalaFLEX 3DR among the BD products with updated warnings and precautions. The letter distinguished their clearance for soft tissue reinforcement from use in breast surgery.

A GalaFLEX claim needs more than the name “internal bra” in a consultation note. Our lawyers want the operative report and product record showing which scaffold was implanted, where it was placed, and what a later surgeon found when treating the complication. Records of infection, tissue breakdown, removal, or revision can help connect the injury to the product rather than to breast surgery generally.

AlloDerm Breast Reconstruction Lawsuits

AlloDerm is an acellular dermal matrix made from donated human tissue. It should not be described as if it were the same device as GalaFLEX. The manufacturer’s current instructions distinguish certain uses to repair a skin defect after mastectomy from uses to extend an implant pocket or keep an implant in position. That makes the actual surgical use important, along with the version of the instructions available at the time.

This warning identifies two specific products associated with increased complications rather than suggesting that every type of breast mesh carries the same risks. For women who experienced complications, the first question is what product was used. Many patients, in fact, most women we talk to, have no idea what brand of mesh their surgeon implanted. They may remember being told that the mesh would provide additional support, but not the name of the product or whether there were known concerns about its safety.

The FDA’s findings also do not mean that every complication involving AlloMax or FlexHD was caused by a defective product. Breast reconstruction is complicated surgery, and infections and implant failures can occur for several reasons. But when federal regulators identify higher complication rates involving particular products, that raises legitimate questions about what manufacturers knew, what warnings they provided to surgeons, and whether patients were adequately informed of the risks. Those questions become especially important when a woman undergoes additional operations to correct a problem that may have been associated with the mesh used in her original surgery.

AlloMax and FlexHD: The FDA Complication Warning

The 2021 FDA communication singled out AlloMax and FlexHD for potentially higher complication rates in implant-based breast reconstruction. Australia’s Therapeutic Goods Administration summarized the FDA analysis, including higher rates of major complications, additional operations, infection, and implant removal. It also explained that the underlying data predominantly involved an older FlexHD formulation.

That warning gives an investigation a more specific starting point than a general statement about breast mesh. We need to identify the formulation, the surgery date, the warnings supplied to the surgeon, and the complication that followed. The findings should not be transferred automatically to AlloDerm, GalaFLEX, or every later version of FlexHD.

Internal Bra Complications: What Can Go Wrong

Breast surgery involving mesh can lead to serious complications, although many of these problems can also occur in breast implant surgery without mesh. The key issue in a mesh injury case is whether the mesh contributed to the complication, made it worse, required removal, or created risks that were not adequately disclosed before surgery.

The records from a revision operation can be especially useful. Did the surgeon remove infected mesh, find exposed material or tissue breakdown, or document a failure of support? Pathology and treatment notes may help explain what happened. That is the evidence our lawyers look for when deciding whether a complication supports a claim against the mesh manufacturer.

The human body does not always tolerate foreign material. Whether the mesh is biologic or synthetic, the immune system can react in the weeks immediately following surgery or months or years later. Reported complications in breast mesh cases include infection, seroma, capsular contracture, mesh migration or failure, skin erosion, tissue necrosis, chronic pain, nerve symptoms, and implant loss.

A 2024 study published in Aesthetic Surgery Journal Open Forum reviewed synthetic mesh outcomes in alloplastic breast reconstruction. The comparative studies found no statistically significant difference in infection risk and lower reoperation and explant risks with synthetic mesh than with biologic mesh. Those results do not prove that synthetic mesh generally performs worse. Our lawyers must examine the particular product, procedure, and complication, rather than treat all mesh as interchangeable.

How to Find Out If Mesh Was Used in Your Surgery

Many patients are never explicitly told that mesh was part of their procedure. Surgeons often describe the internal bra technique in general terms without naming specific products, and the details are buried in surgical records that patients rarely think to request.

You can do this yourself or, more likely, your attorney will do it for you. To identify whether mesh was used and which brand you received:

• Request your complete operative report from the hospital or surgical center. This document describes exactly what was done during your procedure, including any materials implanted.
• Look for device implant stickers. Hospitals often attach product stickers from implanted devices to the surgical record. These may contain the brand name, product code, lot number, and Unique Device Identifier.
• Review discharge paperwork and implant documentation cards given to you at the time of surgery. This can be a shortcut to finding the brand, but it is not necessary if you no longer have the paperwork.
• Call your surgeon’s office and ask directly whether mesh or acellular dermal matrix was used and, if so, the specific brand and product name.

Your medical records belong to you by law. We rarely have trouble obtaining them. If a provider creates obstacles to access, an attorney can issue a formal medical records request on your behalf. Identifying the specific product you received is one of the first steps our legal team will take when evaluating your claim.

Evidence That Strengthens a Breast Mesh Claim

Personal injury claims rest on documentation. You do not need everything assembled before speaking with an attorney, but gathering what you can now puts your case in a stronger position from the start.

Many women wait to seek legal advice because they are still in treatment or are not sure their situation rises to the level of a lawsuit. That hesitation is understandable, but it can cost you. Evidence disappears, statutes of limitations run, and the window to act can close without warning. You do not need a complete file before calling. We can listen to what happened, identify the records we need, and help determine whether the mesh may be connected to your injuries.

Breast Mesh Lawsuit Settlements and Potential Case Value

We are in the early innings of this litigation. As of 2026, there are no large-scale breast mesh settlements. Because the litigation is still developing, specific figures are difficult to provide. What is available is context from comparable mesh litigation.

In October 2024, BD, the parent company of C.R. Bard, announced an agreement to resolve the vast majority of its existing hernia litigation. The settlement terms were confidential, so the announcement does not establish a publicly confirmed $1 billion payout or an average claim value. Bard also faces scrutiny over breast mesh products, including AlloMax and Phasix.

Hernia mesh and breast mesh cases involve different injuries, different medical uses, and different patient populations. But the hernia mesh litigation shows that mesh manufacturers can face major liability when plaintiffs prove that a product caused widespread harm and that warnings did not match what the company knew about risk.

These internal bra lawsuits may have significant settlement value, especially in cases involving revision surgery, implant loss, infection, permanent deformity, tissue damage, chronic pain, or evidence that the manufacturer promoted breast use despite knowing the product had not been adequately evaluated for that purpose.

The value of any individual breast mesh claim depends on several factors:

The internal documents will matter. Plaintiffs will want to know what manufacturers knew about breast-specific complication rates, when they knew it, how they described those risks internally, and whether the warnings given to surgeons matched the concerns reflected in company files.

From there, if defendants do not resolve the cases, bellwether trials may eventually help establish settlement ranges. These are early test cases that go to a jury verdict and give both sides a clearer picture of risk. The reality is that this process often takes time, especially once cases begin consolidating in federal or state court.

Frequently Asked Questions About Breast Mesh Lawsuits

Hiring an Internal Bra Mesh Lawyer

If you believe you have a claim in this litigation, our law firm wants to help you. These cases require product identification, medical record review, FDA and labeling analysis, statute of limitations review, and a close look at your complications and revision history.

Call 800-553-8082 or get a free, no-obligation consultation online. You do not need to know the brand of mesh before calling. If the facts suggest a viable claim, our lawyers can help identify the product and determine whether your injuries may fit the internal bra mesh litigation.